Rethinking triglycerides in the management of ASCVD

Clicks: 1
ID: 319561
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #185 of 194 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Triglycerides have traditionally occupied an uncertain role in atherosclerotic cardiovascular disease (ASCVD) prevention, often considered secondary to low-density lipoprotein cholesterol (LDL-C). Emerging evidence indicates that triglycerides are best viewed not as a direct cause of atherosclerosis, but as a clinical marker of triglyceride-rich lipoprotein (TGRL) and remnant particle burden. These apolipoprotein B–containing particles can enter the arterial wall, promote lipid deposition, and amplify vascular inflammation. Genetic and Mendelian randomization studies support a causal link between remnant lipoproteins and ASCVD that is independent of LDL-C levels and proportional to atherogenic particle number. Despite effective LDL-C lowering, substantial residual ASCVD risk persists, particularly in patients with diabetes mellitus, obesity, and metabolic dysfunction. However, reducing triglyceride concentrations alone does not consistently translate into fewer cardiovascular events. Clinical benefit appears to depend on whether therapy meaningfully reduces atherogenic particle burden or modifies causal pathways. Icosapent ethyl has demonstrated reductions in major adverse cardiovascular events, although the mechanism of benefit remains incompletely understood and is not explained entirely by triglyceride lowering. Fibrates have shown modest benefit in selected populations, whereas mixed omega-3 formulations have not consistently demonstrated cardiovascular risk reduction. Emerging therapies targeting key regulators of remnant metabolism, including apolipoprotein C-III and angiopoietin-like protein 3, offer more direct approaches to modifying causal pathways. In contemporary practice, triglycerides should be interpreted longitudinally within a framework of remnant lipoprotein biology and residual cardiovascular risk rather than pursued as an isolated therapeutic target.
Reference Key
openalex_W7167241604 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors S. Khanna, Deepak L Bhatt, Peter Libby, A. Bhat
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag341
URL
https://doi.org/10.1093/eurjpc/zwag341
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.